Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?

References

• Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342:1477-83
   PubMed Web of Science ®Google Scholar
• Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013;342:1484-90
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33
   PubMed Web of Science ®Google Scholar
• Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013;341:1199-204
   PubMed Web of Science ®Google Scholar
• Sanders RW, Derking R, Cupo A, et al. A next-generation cleaved, soluble HIV-1 envelope Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9:e1003618
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
   PubMed Web of Science ®Google Scholar
• Ringe RP, Sanders RW, Yasmeen A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 2013;110:18256-61
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhu J, Wu X, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013;39:245-58
   PubMed Web of Science ®Google Scholar
• Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013;9:e1003106
   PubMed Web of Science ®Google Scholar
• Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013;340:711-16
   PubMed Web of Science ®Google Scholar
• Ota T, Doyle-Cooper C, Cooper AB, et al. Cell lines as candidate vaccine biosensors. J Immunol 2012;189:4816-24
   PubMed Web of Science ®Google Scholar
• Scharf L, West AP Jr, Gao H, et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci USA 2013;110:6049-54
   PubMedGoogle Scholar
• West AP Jr, Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 2012;109:E2083-90
   PubMedGoogle Scholar
• McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013;210:655-63
   PubMed Web of Science ®Google Scholar
• McGuire AT, Glenn JA, Lippy A, Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 2013;88(5):2645-57
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467:591-5
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013;496:469-76
   PubMed Web of Science ®Google Scholar
• Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013;110:18214-19
   PubMed Web of Science ®Google Scholar
• Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012;30:429-57
   PubMed Web of Science ®Google Scholar
• Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013;153:126-38
   PubMed Web of Science ®Google Scholar
• Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 2014;192:1100-6
   PubMedGoogle Scholar
• Malherbe DC, Doria-Rose NA, Misher L, et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011;85:5262-74
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Bhiman JN, Gray ES, et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013;9:e1003738
   PubMed Web of Science ®Google Scholar
• Bartesaghi A, Merk A, Borgnia MJ, et al. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 2013;20:1352-7
   PubMed Web of Science ®Google Scholar